Jeffrey Silber
Vermogen: 579 662 $ op 31-07-2026
Vermogen: 579 662 $ op 31-07-2026
Jeffrey Silber currently works at Ironwood Pharmaceuticals, Inc., as Head-Research & Drug Development from 2026.
Dr. Silber also formerly worked at Vedanta Biosciences, Inc., as Chief Medical Officer from 2020 to 2026.
Dr. Silber received his undergraduate degree from Harvard University and doctorate degree from Albert Einstein College of Medicine, Inc.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 20-07-2026 | 137.036 ( 0,08% ) | 579 662 $ | 31-07-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| IRONWOOD PHARMACEUTICALS, INC. | Hoofd Techniek/Wetenschap/O&O | 20-07-2026 |
| Bedrijven | Functie | Einde |
|---|---|---|
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Develops microbial therapies that address the human immune system | Hoofd Techniek/Wetenschap/O&O | 01-07-2026 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets gastrointestinal products | Health Technology |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Albert Einstein College of Medicine, Inc.
Albert Einstein College of Medicine, Inc. Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Develops microbial therapies that address the human immune system | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau